secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001193125-22-302201
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx and Kite Pharma enter CAR T-cell therapy collaboration; $225M upfront + $100M equity
--------------------------------------------------------------------------------

- Collaboration and License Agreement with Kite Pharma (Gilead) for CART-ddBCMA, a CAR T therapy for myeloma.
- Arcellx receives $225M upfront cash payment and $100M equity investment from Kite.
- Eligible for milestones up to $635M per NextGen Product and $508M per Non-Auto Product.
- Arcellx retains co-development/co-commercialization option and royalties on Licensed Products.
- Deal subject to HSR review and other regulatory approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312522302201/0001193125-22-302201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312522302201/d378409d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-302201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer